Skip to content

Flashstack

Severity weighted live coverage

CriticalLead signal100% confidence3 hr ago

Shooting at lake near Oklahoma City leaves at least 10 wounded, police say

Alert me
VistoaGuestSign in to save
HomeTopicsSearch
  • Home
  • Search
  • Saved
  • Me
Saved
Me
Now trendingMethodologySettingsHelp

Grist

May 4, 2026

Should Roundup labels warn users about the cancer risk? It’s up to the Supreme Court.
Gristby Ayurella Horn-Muller·May 4, 2026

Should Roundup labels warn users about the cancer risk? It’s up to the Supreme Court.

Political leanleft 0.77Source quality71/100Factual ratio75/100Framing50/100

Since 2018, when it bought the chemical manufacturer Monsanto, the German conglomerate Bayer has set aside billions to settle legal claims that the active ingredient in the company’s weedkiller Roundup has caused cancer and other health issues among its users. More than 100,000 plaintiffs across the U.S. have filed lawsuits alleging a cancer link, and in February the company agreed to settle a class-action lawsuit for $7.25 billion. Last week, the Supreme Court heard oral arguments in one case that didn’t reach a settlement. John Durnell first sued Monsanto in 2019, arguing that he developed non-Hodgkin lymphoma because of persistent exposure to glyphosate in Roundup, which he had regularly sprayed throughout his neighborhood for twenty years. In 2023, the Missouri jury found Monsanto liable for failing to warn users of the cancer risk from glyphosate, and awarded Durnell $1.25 million in damages. The company has denied the claims and issued a series of appeals ever since. Under the Federal Insecticide, Fungicide, and Rodenticide Act — known as FIFRA — the Environmental Protection Agency is authorized to govern the sale and labeling of pesticides. The federal law bars pesticides that are “misbranded,” or lack warnings that may be necessary to protect

Read at GristCompare full coverage

Lean: -0.765 · Source quality 71/100 · Factual vs opinion 75/100.

Score signature

Political lean

Political leanleft 0.77Source quality71/100Factual ratio
75/100
Framing50/100

Methodology

v2-canonical
100
Source diversity
across 1 outlet
Compare full coverage